

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Moviprep

By registered health care professionals for

Bowel cleansing

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 100

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

Reference number: 100 Valid from: 06/2021 Review date: 06/2023

2. Medicines practice guideline 2: Patient group directions

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care <u>PGD</u> website FAQs

3. PGD development

Refer to the <u>NICE PGD competency framework for people developing PGDs</u>

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the NICE PGD competency framework for people authorising PGDs

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

Reference number: 100 Valid from: 06/2021 Review date: 06/2023

5. PGD adoption by the provider

Refer to the <u>NICE PGD competency framework for people authorising PGDs</u>

Job title and organisation	Signature	Date	Applicable or not applicable to area

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the <u>NICE PGD competency framework for health professionals using PGDs</u>

	Requirements of registered Healthcare professionals working under the PGD	
Qualifications and	Registered healthcare professionals, working within or	
professional registration	contracted by the Manx Care, GP practice or Hospice who are	
	permitted staff groups outlined within the current PGD policy	
	Pharmacists must be practising in Manx Care authorised	
	premises i.e. contracted pharmacy premises	
Initial training	Knowledge of current guidelines and the administration of the	
	drug specified in this PGD/BNF and of the inclusion and	
	exclusion criteria	
	Training which enables the practitioner to make a clinical	
	assessment to establish the need for the medication covered by	
	this PGD	
	Local training in the use of PGD's	
Competency	Staff will be assessed on their knowledge of drugs and clinical	
assessment	assessment as part the competency framework for registered health	
	professionals using PGD's	
Ongoing training and	The registered health care professionals should make sure they are	
competency	aware of any changes to the recommendations for this medication;	
	it is the responsibility of the registered health care professionals to	
	keep up to date with continuing professional development. PGD	
	updates will be held every two years	

Reference number: 100 Valid from: 06/2021 Review date: 06/2023

7. Clinical Conditions

Clinical condition or	Bowel cleansing
situation to which this	bower cicurising
PGD applies	
Inclusion criteria	Patient aged 18 years or over
merasion enteria	 Patient has a valid referral and appointment for colonoscopy
	investigation, requiring oral bowel cleansing agent prior to
	procedure
	 Less than 12hours time prior to investigation
Exclusion criteria	Acute intestinal ulceration
Exclusion enteria	Addison's disease
	 Allergy and hypersensitivity to Moviprep, or any of its
	ingredients
	Cardiac arrhythmias
	G6PD deficiency
	Hypovolaemia
	Ileostomy
	Phenylketonuria
	Reduced consciousness
	 Suspected gastrointestinal obstruction or perforation
	Severe inflammatory bowel disease
	Severe renal impairment eGFR<30ml/min
Cautions (including any	Diabetes Mellitus
relevant action to be	Dementia
taken)	 Patients with reduced mobility and/or is a falls risk
, and the same of	Abdominal pain/bloating
	Rectal irritation
	Sleep disturbance
Arrangements for referral	Patient should be referred to a more experienced clinical
for medical advice	practitioner for further assessment
Action to be taken if	Patient should be referred to a more experienced clinical
patient excluded	practitioner for further assessment
Action to be taken if	A verbal explanation should be given to the patient on: the need
patient declines	for the medication and any possible effects or potential risks
treatment	which may occur as a result of refusing treatment
	This information must be documented in the patients' health
	records
	Any patient who declines care must have demonstrated capacity
	to do so
	Where appropriate care should be escalated

Reference number: 100 Valid from: 06/2021 Review date: 06/2023

8. Details of the medicine

Name, form and strength of medicine	Moviprep: Sachet A: macrogol 3350/sodium sulfate/sodium chloride/ potassium chloride Sachet B: ascorbic acid /sodium ascorbate	
Legal category	Pharmacy (P)	
Indicate any <u>off-label use</u> (if relevant)	None	
Route/method of	Oral	
administration	Orai	
Dose and frequency	2 x sachets to be given as indicated:	
	 AM investigation appointment: Do not eat after 13:00 the day before procedure Continue drinking clear fluids only until fasting instructions dictate Sachet 1 to be taken @ 17:00, and Sachet 2 to be taken @ 20:00 on the day before procedure. Drink an additional 500mls of clear fluid during that evening PM investigation appointment: Do not eat after 15:00 the day before procedure Continue drinking clear fluids only until fasting instructions dictate Sachet 1 to be taken @ 17:00 the day before the procedure. Drink an additional 500mls of clear fluid during that evening Sachet 2 to be taken @ 18:00 on morning of the procedure. Drink an additional 500mls of clear fluid during that morning. Continue drinking clear fluids only until fasting instructions dictate (refer to diet advice sheet provided to patient for further information) 	
Quantity to be supplied	2 x sachets	
Maximum or minimum	One episode of care	
treatment period		
Storage	Room temperature	
Adverse effects	Abdominal pain/bloating	
	Rectal irritation	
	Sleep disturbance	
Records to be kept	The administration of any medication given under a PGD must be recorded within the patient's medical records	

Reference number: 100 Valid from: 06/2021 Review date: 06/2023

9. Patient information

Verbal/Written	Verbal information must be given to patients and or carers for all
information to be given to	medication being administered under a PGD
patient or carer	Where medication is being supplied under a PGD, written
	patient information leaflet must also be supplied
	A patient information leaflet is available on request
Follow-up advice to be	If symptoms do not improve or worsen or you become unwell, seek
given to patient or carer	medical advice immediately

10. Appendix A

References

- 1. British National Formulary (BNF) available online: https://bnf.nice.org.uk
- 2. Nursing and Midwifery (2018) "The code" available online: https://www.nmc.org.uk
- 3. Current Health Care Professions Council standards of practice
- 4. General Pharmaceutical Council standards
- 5. The General Optical Council
- 6. Electronic medicines compendium available online: https://www.medicines.org.uk

11. Appendix B

Health professionals agreed to practice

- Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor
- A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves

Reference number: 100 Valid from: 06/2021 Review date: 06/2023